drugset / Trial / NCT01787396

Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d

NCT01787396

Phase 3 Completed 433 enrolled LG Life Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate efficacy and safety of initial combination therapy with Gemigliptin 50mg q.d and Metformin q.d compared with either monotherapy in treatment naïve patients with type 2 diabetes, In other words, to proof superiority of initial combination therapy with Gemigliptin and Metformin than each monotherapy.

Timeline

Start
2013-04
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg
Subject Metformin Small molecule